Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO--(BUSINESS WIRE)-- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that Natalie Holles, President and Chief Operating Officer, will participate in the following investor conferences in October:
Chardan 3rd Annual Genetic Medicines Conference
Fireside Chat: Monday, October 7, 2019, at 10:30am ET
New York, New York
Jefferies Gene Therapy/Editing Summit
Fireside Chat: Tuesday, October 8, 2019, at 9:10am ET
Panel: “Manufacturing, Dose, and Durability in Gene Therapy,” Tuesday, October 8, 2019, at 10:20am ET
New York, New York
To access live webcasts of the fireside chats, please visit the Events & Presentations page within the Investors + Media section of the Audentes website. Following each conference, a replay of the live webcast will be available on the Audentes website for approximately 30 days. There is no webcast available for the Manufacturing, Dose, and Durability in Gene Therapy panel at the Jefferies Gene Therapy/Editing Summit.
About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases. We are leveraging our AAV gene therapy technology platform and proprietary manufacturing expertise to develop programs across three modalities: gene replacement, vectorized exon skipping, and vectorized RNA knockdown. Our product candidates are showing promising therapeutic profiles in clinical and preclinical studies across a range of neuromuscular diseases. Audentes is a focused, experienced and passionate team driven by the goal of improving the lives of patients.
For more information regarding Audentes, please visit www.audentestx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191001005060/en/
Investor Contact:
Andrew Chang
415.818.1033
[email protected]
Media Contact:
Sarah Spencer
415.957.2020
[email protected]
Source: Audentes Therapeutics, Inc.